| Literature DB >> 26017754 |
Aleksandra Konieczna1, Aneta Szczepańska2, Karolina Sawiuk3, Grzegorz Węgrzyn4, Robert Łyżeń5.
Abstract
BACKGROUND: Previously published reports indicated that some enzymes of the central carbon metabolism (CCM), particularly those involved in glycolysis and the tricarboxylic acid cycle, may contribute to regulation of DNA replication. However, vast majority of such works was performed with the use of cancer cells, in the light of carcinogenesis. On the other hand, recent experiments conducted on bacterial models provided evidence for the direct genetic link between CCM and DNA replication. Therefore, we asked if silencing of genes coding for glycolytic and/or Krebs cycle enzymes may affect the control of DNA replication in normal human fibroblasts.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26017754 PMCID: PMC4446904 DOI: 10.1186/s12860-015-0062-8
Source DB: PubMed Journal: BMC Cell Biol ISSN: 1471-2121 Impact factor: 4.241
Fig. 1Levels of mRNAs of genes coding for glycolytic and tricarboxylic acid cycle enzymes in human dermal fibroblast cells treated with siRNAs. Cells were seeded in 6-well plates, and transfected with siRNAs. After 72 h incubation, total RNA was purified and the level of mRNA was estimated by qPCR analysis. Presented results are mean values from at least three independent experiments, with error bars indicating SD. In each experiment, mRNA level measured in untreated cells was used as a control value (100 %, dashed line). In all experiments, statistically significant differences (p < 0.05 in the t-test) were found relative to the control
Fig. 2Viability of human dermal fibroblasts after silencing of genes coding for glycolytic and tricarboxylic acid cycle enzymes. Cells were seeded in 6-well plates, transfected with siRNAs and synchronized. Following washing, the cells were collected and analyzed by flow cytometry. Presented results are mean values from at least three independent experiments, with error bars indicating SD. In each experiment, mRNA level measured in untreated cells was used as a control value (100 %, dashed line). Statistically significant differences relative to the control are indicated by asterisks
Fig. 3Effects of siRNA-mediated silencing of glycolityc genes on enterance of cells in S phase. Cells were seeded on Petri dishes, transfected with siRNA specific for indicated gene (□) and synchronized. Analogous experiments without siRNA were treated as controls (■). After cell cycle releasing, the cells were collected every two hours, starting from 14 h, and analyzed by flow cytometry. Presented results are mean values from at least three independent experiments, with error bars indicating SD. Statistically significant differences relative to the control are indicated by asterisks
Fig. 4Effects of siRNA-mediated silencing of tricarboxylic acid cycle genes on enterance of cells in S phase. Cells were seeded on Petri dishes, transfected with siRNA specific for indicated gene (□) and synchronized. Analogous experiments without siRNA were treated as controls (■). After cell cycle releasing, the cells were collected every two hours, starting from 14 h, and analyzed by flow cytometry. Presented results are mean values from at least three independent experiments, with error bars indicating SD. Statistically significant differences relative to the control are indicated by asterisks
Fig. 5DNA synthesis in human dermal fibroblasts treated with siRNAs. Following siRNA trasfection and synchronization, cells were labeled with BrdU for 24 h. Then, the cells were fixed, and incubated with anti-BrdU antibodies. BrdU incorporation was quantified by a colorimetric reaction (absorbance at 460 nm). Presented results are mean values from at least three independent experiments, with error bars indicating SD. In each experiment, DNA synthesis level measured in untreated cells was used as a control value (100 %, dashed line). Statistically significant differences relative to the control are indicated by asterisks
Fig. 6The scheme of glycolysis and the tricarboxylic acid cycle, with indicated enzymes which impaired production, due to silencing of corresponding genes, resulted in less efficient (marked in red bold font) or delayed (marked in blue bold font) enterance of human dermal fibroblasts to the S phase. Abbreviations: ACO - aconitase; ALDO - fructose-bisphosphate aldolase; CS - citrate synthase; ENO - enolase; FH - fumarase; GAPDH - glyceraldehyde phosphate dehydrogenase; GPI - phosphoglucose isomerase; HK - hexokinase; IDH - isocitrate dehydrogenase; LDH - lactate dehydrogenase; MDH - malate dehydrogenase; OGDH - α-ketoglutarate dehydrogenase; PC - pyruvate carboxylase; PDH - puryvate dehydrogenase; PFK - phosphofructokinase; PGK - phosphoglycerate kinase; PGAM - phosphoglycerate mutase; PKM - pyruvate kinase; SCS - succinyl-CoA synthetase; SDH - succinate dehydrogenase; TPI - triosephosphate isomerase. Abbreviations of metabolite names are as follows: 1,3BPG - 1,3-bisphosphoglycerate; 2PG - 2-phosphoglycerate; 3-P-G - 3-phosphoglycerate; AC-CoA - Acetyl-CoA; CIT - citrate; DHAP - dihydroxyacetone phosphate; F1,6BP - fructose 1,6-bisphosphate; F6P - fructose 6-phosphate; FUM - fumarate; G6P - glucose 6-phosphate; GADP - glyceraldehyde 3-phosphate; ICT - isocitrate; MAL - malate; OXA - oxaloacetate; PEP - phosphoenolpyruvate; Pyr - pyruvate; SUC - succinate; SUC-CoA - α-ketoglutarate
Primers used for real-time qPCR to estimate mRNA levels of particular genes
| Gene name: | Primer sequence | Reference genes |
|---|---|---|
|
|
| GUSB, HPRT |
|
| ||
|
|
| TBP, ACTB |
|
| ||
|
|
| GUSB, HPRT |
|
| ||
|
|
| TBP, ACTB |
|
|
| GUSB, HPRT |
|
| ||
|
|
| TBP, ACTB |
|
| ||
|
|
| TBP, ACTB |
|
| ||
|
|
| TBP, ACTB |
|
| ||
|
|
| GUSB, HPRT |
|
| ||
|
|
| TBP, ACTB |
|
| ||
|
|
| TBP, ACTB |
|
| ||
|
| F: 5’- TCCGACCCTTACCTGTCCTT | TBP, ACTB |
| R: 5’- ACTTCCTGATTTGCCAGTCC | ||
|
| F: 5’- AGATTGTGTATGGACACCTGGA | HPRT, GUSB |
| R: 5’- TACGACTTGCCTCGCTCAAT | ||
|
| F: 5’- CCATCATCTGCAAAAACATCC | HPRT, GUSB |
| R: 5’- CCAATGGTGATGGGCTTG | ||
|
| F: 5’- GCCCAATCTCTATGGGAACA | TBP, ACTB |
| R: 5’- CAGGGACCACACCAGCTC | ||
| OGDH | F: 5’- AGAGTCCCCTTCCCCTGAG | TBP, ACTB |
| R: 5’- GCTTCTACCAGGGACTGTCC | ||
|
| F: 5’- AGCCAGCCAACTTCTTGGA | TBP, ACTB |
| R: 5’- GGATGGCTTCAACCTTAGGA | ||
|
| F: 5’- CAGCACAGGGAGGAATCAAT | HPRT, GUSB |
| R: 5’- CTGCTCCGTCATGTAGTGGA | ||
|
| F: 5’- TGAATGTTTTCAAGCCAATGAT | HPRT, GUSB |
| R: 5’- CCACCACGCAGTTTTCTGTA | ||
|
| F: 5’- CAGGACCAGCTGACAGCAC | TBP, ACTB |
| R: 5’- AGCCTGCTCCGGCTTTAG |